Exelixis, Inc. (EXEL) on Decifer

Decifer ranks EXEL number 27 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 30% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 13% a year, profits grew 60% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• A partly recognized specialty drug owner with returns of 30%, profits up 60%, and momentum of 17 out of 35 above trend makes a genuinely investible setup.

The current read

The evidence on EXEL lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full EXEL research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.